Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. Choi BS, et al. Among authors: ivy sp. Cancer Chemother Pharmacol. 2010 Oct;66(5):973-80. doi: 10.1007/s00280-010-1250-z. Epub 2010 Feb 2. Cancer Chemother Pharmacol. 2010. PMID: 20127092 Free PMC article. Clinical Trial.
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC. Krishnamurthi SS, et al. Among authors: ivy sp. Cancer Chemother Pharmacol. 2009 Feb;63(3):441-50. doi: 10.1007/s00280-008-0754-2. Epub 2008 Apr 15. Cancer Chemother Pharmacol. 2009. PMID: 18414865 Free PMC article. Clinical Trial.
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Brell JM, Krishnamurthi SS, Javle M, Saltzman J, Wollner I, Pelley R, Dowlati A, Kantharaj BN, Schluchter MD, Rath L, Ivy SP, Remick SC. Brell JM, et al. Among authors: ivy sp. Cancer Chemother Pharmacol. 2009 Apr;63(5):851-7. doi: 10.1007/s00280-008-0807-6. Epub 2008 Aug 1. Cancer Chemother Pharmacol. 2009. PMID: 18670776 Free PMC article. Clinical Trial.
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton A, LoRusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy SP, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D. Leal TB, et al. Among authors: ivy sp. Cancer Chemother Pharmacol. 2011 Dec;68(6):1439-47. doi: 10.1007/s00280-011-1637-5. Epub 2011 Apr 9. Cancer Chemother Pharmacol. 2011. PMID: 21479634 Free PMC article.
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, Larson SM, Schwartz LH, Curley T, DeLaCruz A, Ye Q, Heller G, Egorin MJ, Ivy SP, Rosen N, Scher HI, Solit DB. Iyer G, et al. Among authors: ivy sp. Cancer Chemother Pharmacol. 2012 Apr;69(4):1089-97. doi: 10.1007/s00280-011-1789-3. Epub 2011 Nov 29. Cancer Chemother Pharmacol. 2012. PMID: 22124669 Free PMC article. Clinical Trial.
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T. Mortazavi A, et al. Among authors: ivy sp. Invest New Drugs. 2013 Jun;31(3):685-95. doi: 10.1007/s10637-012-9863-1. Epub 2012 Jul 31. Invest New Drugs. 2013. PMID: 22847785 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Ramanathan RK, Fakih M, Mani S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ. Ramanathan RK, et al. Among authors: ivy sp. Cancer Chemother Pharmacol. 2006 Apr;57(4):465-74. doi: 10.1007/s00280-005-0071-y. Epub 2005 Aug 25. Cancer Chemother Pharmacol. 2006. PMID: 16133531 Clinical Trial.
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. Solit DB, et al. Among authors: ivy sp. Clin Cancer Res. 2007 Mar 15;13(6):1775-82. doi: 10.1158/1078-0432.CCR-06-1863. Clin Cancer Res. 2007. PMID: 17363532 Free PMC article. Clinical Trial.
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC. Weigel BJ, et al. Among authors: ivy sp. Clin Cancer Res. 2007 Mar 15;13(6):1789-93. doi: 10.1158/1078-0432.CCR-06-2270. Clin Cancer Res. 2007. PMID: 17363534 Clinical Trial.
169 results